Welcome to our dedicated page for Ufp Technologies news (Ticker: UFPT), a resource for investors and traders seeking the latest updates and insights on Ufp Technologies stock.
UFP Technologies Inc. reports developments for a contract development and manufacturing organization focused on single-use and single-patient medical devices. Company news commonly covers quarterly and annual results, non-GAAP measures such as adjusted EBITDA and adjusted EPS, program ramps, backlog commentary, acquisition integration, and manufacturing capacity tied to medical-device customers.
Updates also include customer supply agreements, new program launches, investor conference participation, and governance matters such as executive succession planning. The company's products and components are used across medical device, wound care, infection prevention, minimally invasive surgery, wearable, orthopedic soft-goods, and orthopedic implant-packaging applications.
UFP Technologies, Inc. (Nasdaq: UFPT) reported a notable increase in Q3 2021 financial performance. Net income reached $3.8 million ($0.50 per share), up from $3.0 million ($0.40 per share) in Q3 2020. Sales surged 17.1% to $50.7 million year-over-year, with sales to the medical market climbing 20.5%. Year-to-date net income stood at $12.7 million, a 38% increase from 2020. However, gross margin decreased to 23.7% from 24.3% in Q3 2020. The CEO highlighted challenges including labor shortages and supply chain issues but expressed optimism about future growth and ongoing acquisitions.
AliMed, Inc. has appointed Adam S. Epstein as the new Chief Executive Officer, effective immediately. Epstein, previously the Chief Commercial Officer, aims to strengthen the company's operations and product portfolio serving leading healthcare providers. AliMed, known for its innovative medical supplies, has focused on growth through partnerships with national GPOs and IDNs while enhancing product development. Under Epstein's leadership, AliMed seeks to improve patient outcomes through its comprehensive healthcare offerings.
UFP Technologies, Inc. (Nasdaq: UFPT) has acquired Contech Medical, Inc., a leader in class III medical device packaging, primarily for catheters and guidewires, with annual sales of approximately $18 million. This acquisition is seen as a strategic fit, allowing UFP to enhance its medical offerings and strengthen customer relationships, as about 70% of Contech’s customers are already UFP clients. The deal is expected to be immediately accretive to earnings and capitalize on the strong growth potential of the medical market.
On September 21, 2021, UFP Technologies, Inc. (Nasdaq: UFPT) announced that CEO R. Jeffrey Bailly and CFO Ron Lataille will present at the Sidoti Fall Virtual Investor Conference scheduled for September 22-23, 2021. The live presentation will start at 10:00 A.M. ET on September 22 and can be accessed here. Additionally, one-on-one meetings with investors will be hosted by the company on the same day. Registration is free and open to all interested parties.
UFP Technologies (Nasdaq: UFPT) announced that CEO Jeff Bailly and CFO Ron Lataille will present at the virtual Midwest IDEAS Investor Conference on August 26, 2021. The company specializes in designing and manufacturing components and packaging for the medical sector, utilizing advanced materials like foams and plastics. UFP also serves diverse markets, including aerospace and automotive. This conference aims to connect quality companies with investment professionals, fostering regional investment communities.
UFP Technologies, Inc. (Nasdaq: UFPT) reported a strong second quarter for 2021, achieving net income of $4.7 million ($0.62 per diluted share), up from $2.3 million ($0.31 per diluted share) in Q2 2020. Sales reached $50.7 million, an 18.8% increase from $42.6 million last year. Year-to-date, net income was $8.9 million, compared to $6.2 million the previous year. Gross margins improved to 26.5%. While challenges in raw material availability and labor shortages persist, the company remains optimistic about growth opportunities and strategic initiatives.
UFP Technologies (Nasdaq: UFPT), a leading designer and manufacturer for the medical market, will participate in the virtual East Coast IDEAS Investor Conference on June 16, 2021. CEO Jeff Bailly and CFO Ron Lataille will present and conduct one-on-one investor meetings. Interested investors can contact Jeff Elliott at Three Part Advisors for participation details. UFP Technologies specializes in creating components using specialized foams and materials, serving various sectors like aerospace, automotive, and industrial markets.
UFP Technologies (Nasdaq: UFPT) reported Q1 2021 net income of $4.2 million ($0.55/share), up from $3.9 million ($0.52/share) in Q1 2020. Sales rose 0.7% to $48.6 million, with a notable performance in Aerospace & Defense and Consumer markets, growing 68% and 62%, respectively. Medical sales, however, fell by 11.5%. Gross profit margin decreased to 25.9%, while SG&A expenses dropped to 15.0%. The company is optimistic about recovery as elective procedures resume and is focused on strategic initiatives for growth.
UFP Technologies, Inc. (Nasdaq: UFPT) announced its participation in the virtual Sidoti Conference on March 24, 2021. Chairman and CEO R. Jeffrey Bailly and CFO Ron Lataille will present at 9:15 AM ET. Investors can access the presentation through the conference portal or visit the company's investor relations section online. UFP Technologies specializes in designing and manufacturing components for the medical market and uses advanced materials and techniques for production.
UFP Technologies reported a net income of $13.4 million ($1.77 per share) for the year ended December 31, 2020, down from $19.8 million ($2.63 per share) in 2019. Sales decreased by 9.6% to $179.4 million. In Q4 2020, net income fell to $4.2 million ($0.55 per share), down from $5.8 million in Q4 2019. Medical sales dropped 6.8% for the year, primarily due to a decline in elective surgeries. However, the Product Development business surged 63%. The company noted improvements in gross margins and expressed optimism for a rebound in sales by Q4 2021.